ADA 2017: Insulins go Head-to-Head

Insulin degludec vs glargine--which costs less per anum and why? We summarize this study and 2 other direct insulin comparisons reported at ADA 2017.

Studies at the American Diabetes Association (ADA) 77th Scientific Sessions included direct comparisons of a variety of insulin formulations and regimens. Click through the slides above for summaries of 3 studies that evaluate basal insulins in elderly patients; examine the differences between an insulin/oral agent vs insulin only regimen; and report on a cost-benefit analysis of insulin glargine vs insulin degludec -- one costs less because it causes less hypoglycemia.

Related Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
Related Content
© 2023 MJH Life Sciences

All rights reserved.